The effect of azithromycin in treatment of COVID19

Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200415047092N1

Enrollment

110

Registered

2020-04-20

Start date

2020-04-24

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-COV2 ASSOCIATED INFECTION. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: These patients receive daily azithromycin 500 mg, bi-daily oseltamivir 75, bi-daily lopinavir/ritonavir or in case of adverse gastrointestinal effects daily atazana

all for 5 days. Intervention 2: Control group: These patients receive bi-daily oseltamivir 75, bi-daily lopinavir/ritonavir or atazanavir (Kaletra) 400/100 mg and in case of adverse gasterointestinal

all drugs are administered for five days.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Obtaining informed consent from patient or patient’s legal proxy for inclusion in this study.- Patients must be over 18 years of age- A documented positive PCR test for SARS-CoV-2 or one of the following criteria:1. Compelling clinical symptoms associated with a covid-19 infection; including: fever, dry cough and dyspnea2. A typically involvement of lungs observed in HRCT or Spiral CT scanning that can be strongly attributed to a covid-19 pneumonia3. Patients that have developed known complications of a covid-19 infection such as acute respiratory distress syndrome (ARDS) or myocarditis.

Exclusion criteria

Exclusion criteria: pregnancy or nursing Patients whose covid-10 infection has not been proven and have symptoms that can be attributed to either the common cold or influenza and/or have had a positive PCR test for influenza. known allergy to chloroquine or hydroxylchloroquine retinopathy G6PD deficiency prolonged QT interval severe heart failure Pacemaker implantation cardiac arrhythmia

Design outcomes

Primary

Measure	Time frame
Peripheral capillary oxygen saturation. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: pulse oximeter.;Admission duration. Timepoint: From the beginning of the hospital visit to the discharge. Method of measurement: Questionnaire.;Fever. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: Mercury thermometer.;Need to ICU admission. Timepoint: During admission. Method of measurement: Questionnaire.	—

Measure

Time frame

Peripheral capillary oxygen saturation. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: pulse oximeter.;Admission duration. Timepoint: From the beginning of the hospital visit to the discharge. Method of measurement: Questionnaire.;Fever. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: Mercury thermometer.;Need to ICU admission. Timepoint: During admission. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Sekhavati Moghadam

Tehran University of Medical Sciences

Dr.esekhavati@gmail.com+98 21 5517 6810

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026